INTRODUCTION {#S1}
============

Dengue virus (DENV) is a serious public health problem, especially in tropical and subtropical areas, and infects up to \~390 million people annually ([@R5]). DENV infection is associated with a range of clinical manifestations, from asymptomatic to mild dengue fever (DF) to more severe and sometimes life-threatening dengue diseases, including dengue hemorrhagic fever (DHF) and dengue shock syndrome (DSS). However, host immunological correlates of severe dengue disease, especially during the acute phase of DENV infection, have not been fully determined.

Both the pathological and protective effects of T cells have been reported during DENV infection ([@R42]; [@R53]; [@R55]; [@R58]; [@R64]; [@R72]). On the one hand, it has been reported that cross-reactive memory T cells that are specific for the primary infecting DENV serotype may expand and lead to immunopathology and ineffective viral clearance during a secondary heterologous infection (called original antigenic sin) ([@R23]; [@R41]; [@R42]; [@R53]; [@R55]; [@R58]; [@R64]; [@R72]). On the other hand, accumulating evidence suggests that T cells may contribute to the control of DENV infection in both mice and humans ([@R13]; [@R14]; [@R20]; [@R50]; [@R66]; [@R73], [@R74]; [@R78], [@R79]; [@R81], [@R82], [@R83]; [@R87]). We and others have previously shown that DENV-specific CD4 memory T cells can produce cytokines such as interferon *g* (IFN-γ), tumor necrosis factor α (TNF-α), and interleukin-2 (IL-2), which are usually associated with T helper type 1 (Th1) cells, following DENV infection and vaccination ([@R21]; [@R24]; [@R36]). Furthermore, human CD4 effector memory T cells re-expressing CD45RA (Temra cells) have been detected in healthy blood bank donors who have been infected with DENV multiple times and show an increased expression of numerous cytotoxic molecules, including CX3CR1, granzyme B, perforin, and CD107a ([@R74]). Subsequent studies further revealed the transcriptomic profile and heterogeneity of CD4 Temra cells in apparently healthy cohorts and identified surface molecules such as GPR56 and CD244 that are uniquely expressed on cytotoxic CD4 Temra cells ([@R47]; [@R65]). However, the phenotype and transcriptomic profile of DENV-specific CD4 T cells during the acute phase of infection and their association with dengue disease severity have not been systematically defined.

In general, IL-10 is an immunosuppressive cytokine that has multifaceted functions in modulating T cell differentiation, memory formation, function, and exhaustion, as well as germinal center B cell responses ([@R12]; [@R32], [@R33]; [@R63]; [@R77]). IL-10 can be produced by multiple cell types from both innate and adaptive immune systems, including dendritic cells (DCs), macrophages, B cells, and CD8 T cells, as well as various CD4 T cell subsets, including Th1 cells, Th2 cells, Foxp3^+^ regulatory T (Treg) cells, and Foxp3^−^ type 1 regulatory T (Tr1) cells ([@R45]). Previous studies have reported that DENV infection can induce the production of IL-10 by monocytes, which may dampen anti-DENV immune responses and viral control ([@R1]; [@R10]; [@R69]; [@R70]). In addition, the increased IL-10 level in the blood is associated with severe dengue disease ([@R9]; [@R11]; [@R15]; [@R16]; [@R19]; [@R39]). However, the production of IL-10 by DENV-specific CD4 T cells and its association with dengue disease severity have not been fully elucidated.

In this study, we set out to determine the production of IL-10 in conjunction with IFN-γ by DENV-specific CD4 T cells, their gene expression profiles, and their association with dengue disease severity. All of the patients with severe dengue who were included in this study had DHF but no other forms of severe dengue, including DSS and organ failure. Our data show that DENV-specific CD4 T cell response during the acute phase of infection consists of a prominent subset that co-produced IL-10 and IFN-γ. DENV-specific IL-10^+^IFN-γ^+^ double-positive (DP) cells were largely phenotypically homogeneous and exhibited non-cytotoxic/Tr1 gene signatures such as *IL-21, IL-22, CD109,* and *CCR1.* Although we detected more DENV-specific DP cells than DF during acute DHF, the phenotype of these cells was largely similar in acute DF and DHF samples. These results suggest that severe dengue disease is not associated with altered cytokine secretion or phenotype of this DP cell subset, arguing against an altered CD4 T cell response as being a determinant of DHF.

RESULTS {#S2}
=======

DENV-Specific IL-10^+^IFN-γ^+^ DP CD4 T Cells Are Prominent during Acute DENV Infection {#S3}
---------------------------------------------------------------------------------------

Previous studies have reported increased IL-10 production during acute DENV infection ([@R10]; [@R69]; [@R70]). However, whether DENV-specific CD4T cells may be responsible for IL-10 production was not addressed. We previously described a pool of 180 different CD4 T cell epitopes derived from DENV1--4 that allows broad coverage of anti-DENV CD4 T cell responses ([@R20]; [@R75]). Hereafter, this epitope "megapool" is referred to as DENV MP. In the present study, peripheral blood mononuclear cells (PBMCs) from hospitalized DF or DHF Sri Lankan patients collected during the acute phase, discharge, and convalescent phase time points were stimulated *ex vivo* with the DENV MP, and the production of IFN-γ and IL-10 by DENV-specific CD4 T cells was assessed by cytokine secretion assay and flow cytometry analysis. As shown in [Figure 1A](#F1){ref-type="fig"} for a representative donor, DENV-specific CD4 T cells from PBMCs collected during acute DENV infection produced IFN-γ and/or IL-10 in response to epitope stimulation. In addition to IL-10^+^IFN-γ^−^ IL-10 single-positive (SP) and IL-10^−^IFN-γ^+^ IFN-γ SP cells, we observed a prominent IL-10^+^IFN-γ^+^ DP population ([Figure 1A](#F1){ref-type="fig"}). When the responses of 17 different acute DENV infection samples were considered, the magnitudes of IFN-γ SP and DP responses were significantly higher than that of the IL-10 SP response, whereas no major difference was observed between the magnitudes of IFN-γ SP and DP responses ([Figure 1B](#F1){ref-type="fig"}).

We next assessed the kinetics of these DENV-specific CD4 T cell responses using longitudinal samples as a function of acute, discharge, and convalescent time points with a median of 4, 7, and 31 days from fever onset, respectively. As expected, the total DENV-specific CD4 T response (the sum of IL-10 SP, IFN-γ SP, and DP) diminished in discharge and convalescent samples ([Figure 1C](#F1){ref-type="fig"}). This decrease was apparent for all subpopulations, as we observed a substantial decrease in the frequency of IL-10 SP and IFN-γ SP cells ([Figure 1C](#F1){ref-type="fig"}). DENV-specific DP CD4 T cells were absent in the convalescent phase ([Figure 1C](#F1){ref-type="fig"}). As a control, we examined the production of IL-10 and IFN-γ after stimulation with CD3/CD28 or DENV MP in healthy DENV seronegative donors from Sri Lanka and healthy control donors from non-dengue-endemic San Diego, California. Although IFN-γ SP cells were observed following CD3/CD28 stimulation, DP CD4 T cells were not detected in healthy donors ([Figure S1](#SD1){ref-type="supplementary-material"}, supporting the notion that this population is specific to acute dengue patients. These results reveal a prominent DENV-specific IL-10^+^IFN-γ^+^ DP CD4 T cell population during the acute phase, which progressively wanes upon discharge and in convalescence.

DP Cells Are Associated with a Prominent Transcriptome Profile {#S4}
--------------------------------------------------------------

To further characterize the gene expression profiles of the DENV-specific CD4 T cell subsets defined by their production of IFN-γ and IL-10, we isolated DENV-specific IL-10 SP, IFN-γ SP, and DP cells by standard cytometry sorting and performed bulk RNA sequencing (RNA-seq) on these sorted subsets. As a control, we also performed RNA-seq on sorted IL-10^−^ IFN-γ^−^ double-negative (DN) CD4 T cells from the same antigen-stimulated cultures. Principal-component analysis (PCA) was used to visualize the global gene expression patterns of the four CD4 T cell populations. DN and DP cells formed two distinct clusters that were largely separated by principal component 1 (PC1) ([Figure 2A](#F2){ref-type="fig"}). IL-10 SP and IFN-γ SP cells, while more heterogeneous, still mostly clustered closely to DP cells ([Figure 2A](#F2){ref-type="fig"}).

We next analyzed the pattern of genes differentially expressed (DE) between the DP versus DN subsets. A large number of significantly DE genes was identified, and the top 250 DE genes were associated with a rather stringent cutoff threshold of absolute log2 fold change of 3.3, corresponding to \~10-fold. As expected, DP cells upregulated both *IFNG* and *IL10* genes ([Figure 2B](#F2){ref-type="fig"}). Next, pairwise analyses were performed to identify DE genes between the four CD4 T cell subsets, namely IL-10 SP versus DP, IFN-γ SP versus DP, IFN-γ SP versus IL-10 SP, IFN-γ SP versus DN, and IL-10 SP versus DN. Using the same log2 fold change of 3.3 threshold, only 26 DE genes were identified when comparing IL-10 SP versus DP and IFN-γ SP versus DP ([Figure 2B](#F2){ref-type="fig"}). In addition, only 7 DE genes were observed between IL-10 SP and IFN-γ SP cells ([Figure 2B](#F2){ref-type="fig"}), suggesting that the gene expression profiles of IL-10 SP and IFN-γ SP cells resemble that of DP cells, which is also consistent with the PCA analysis shown in [Figure 2A](#F2){ref-type="fig"}. Fewer DE genes were identified by comparing IFN-γ SP versus DN and IL-10 SP versus DN (a total of 119 and 78, respectively, as compared to the 250 DE genes between DP and DN cells using the same cutoff; [Figure 2B](#F2){ref-type="fig"}). *IL10* transcripts were upregulated in IFN-γ SP cells and *IFNG* transcripts were upregulated in IL-10 SP cells ([Figure 2B](#F2){ref-type="fig"}), supporting the notion that these two SP subsets may resemble DP cells but with a less prominent pattern of DE genes. These data also suggest that there is a gradient of differentiation states between these cell populations. These data show that DP cells are associated with a prominent gene expression profile and that IL-10 SP and IFN-γ SP cells may exhibit similar transcriptomic profiles, albeit less pronounced. Thus, we focused on DP cells for the rest of this study.

When the top 250 DE genes in DENV-specific DP cells ([Table S1](#SD2){ref-type="supplementary-material"}) were examined in more detail, we found that DP cells down-regulated several genes normally expressed by naive and memory T cells such as *CCR7, TCF7, IL7R,* and *LEF1,* which are also upregulated in memory precursors in an Foxo1-dependent manner ([@R25]). In contrast, these cells upregulated the expression of genes associated with T cell activation (*IRF4*, *IRF8, CD38*), cytotoxicity (*PRF1*, *GZMB*), cytokines (I*FNG, IL10*), chemokines (*CCL3, CCL4*), and co-stimulation and inhibition (*TNFRSF4, PDCD1*, *ICOS, CTLA4, HAVCR2, LAG3, TNFRSF9*) ([Figure 2C](#F2){ref-type="fig"}). These data reveal a rich and complex gene signature associated with DP cells.

DENV-Specific DP Cells Partially Resemble Cytotoxic CD4 Temra Cells and Tr1-like Cells {#S5}
--------------------------------------------------------------------------------------

Previous studies have described gene signatures associated with human cytotoxic CD4 Temra cells such as granzyme B, perforin, CCL4, CX3CR1, GPR56, T-bet, and CD107a ([@R47]; [@R64], [@R65]; [@R74]), defined in healthy blood donors from hyperendemic areas (and thus corresponding to donors in the convalescent phase well past acute DENV infection). As shown in [Figure S2A](#SD1){ref-type="supplementary-material"}, DENV-specific DP cells associated with acute infection upregulated the expression of *GZMB* (encodes granzyme B), *PRF1* (encodes perforin), and *CCL4.* However, DP cells did not significantly upregulate the expression of *CX3CR1* and *LAMP1* (encodes CD107a) ([Figure S2A](#SD1){ref-type="supplementary-material"}), and *GPR56* was filtered out before DE analysis due to low expression (data now shown). Thus, DENV-specific DP cells express only a portion of the markers that are associated with cytotoxic CD4 Temra cells.

Tr1-like cells lack the expression of the transcription factor Foxp3 and are associated with the expression of multiple activation, inhibitory, and effector molecules such as CTLA4, ICOS, LAG-3, TIM-3, TIGIT, and PD-1, CD49b, and transforming growth factor β (TGF-β) ([@R51]; [@R76]; [@R84]). Similar to Tr1-like cells, DP cells showed an elevated expression of *IFNG, IL10, LAG3, HAVCR2* (encodes Tim-3), *TIGIT, PDCD1* (encodes PD-1), *ICOS, CTLA4,* and *TNFRSF18* (encodes GITR) ([Figure S2B](#SD1){ref-type="supplementary-material"}). However, they did not significantly upregulate *ITGA2* (encodes CD49b), *HLA-DRA,* and *TGFB1* ([Figure S2B](#SD1){ref-type="supplementary-material"}). These data suggest that DENV-specific DP cells express several markers associated with cytotoxic CD4 Temra cells and/or Tr1-like cells and may contain Tr1-like cells.

Non-cytotoxic/Tr1 DE Genes in DP Cells Are Associated with Cytokine Production, Activation, Function, and Migration {#S6}
-------------------------------------------------------------------------------------------------------------------

The vast majority (224, \~90%) of the top 250 DE genes did not overlap with the signature genes of cytotoxic CD4 Temra cells or Tr1-like cells, and we referred to these non-overlapping genes as "non-cytotoxic/Tr1" DE genes of DP cells in this study. DENV-specific DP cells upregulated genes such as *IL21, IL22, CD86, CCL4,* and *CCL5,* while downregulating genes such as *F2RL1, TNFSF13B, S1PR1*, and *PDCD4* ([Figure 3A](#F3){ref-type="fig"}). Pathway and process enrichment analysis revealed that these non-cytotoxic/ Tr1 DE genes are associated with pathways such as T cell activation, cytokine-mediated signaling pathway, and regulation of the lipid metabolic process ([Figure 3B](#F3){ref-type="fig"}). DENV-specific DP cells upregulated numerous cytokine-related genes, including *IL21, IL22, XCL1, CD86, CD70, TNFRSF8* (encodes CD30), *IRF4, IRF8,* and *EGR1*, while downregulating *IL16, PDCD4,* and *TNFSF13B* ([Figure 3C](#F3){ref-type="fig"}). DENV-specific DP cells also showed an increased expression of T cell activation-associated genes, including *CD38, CD109, ZBED2,* and *ZBTB32* ([Figure 3D](#F3){ref-type="fig"}). In addition, DP cells upregulated the expression of *CCR1,* while downregulating the expression of *ITGA5, ITGA5,* and *S1PR1,* suggesting that DP cells may migrate to infected and/or inflammatory sites via migratory molecules such as CCR1 ([Figure 3E](#F3){ref-type="fig"}). These data revealed the gene signatures of DP cells that are associated with cytokine activities, activation, function, and migration.

Expression of Transcription Regulators of CD4 T Cell Lineages {#S7}
-------------------------------------------------------------

To further characterize the phenotype of DENV-specific DP cells, we assessed the gene expression of transcription factors that are crucial for the specification of several major CD4 T cell lineages, including Th1, Th2, Th17, Treg, and follicular T helper (Tfh) cells ([@R68]). In terms of early response signal transducer and activator of transcription (STAT) factors, DENV-specific DP cells had a lower expression of STAT1 and STAT6 but a higher expression of STAT3 than DN cells ([Figure 4](#F4){ref-type="fig"}). STAT3 is involved in the differentiation of Th17 cells and Tfh cells ([@R68]); however, DP cells did not upregulate *RORC* and *BCL6* ([Figure 4](#F4){ref-type="fig"}), which are the master regulators of Th17 and Tfh cells, respectively ([@R68]). DP cells also had a lower expression of *GATA3* and *FOXP3* ([Figure 4](#F4){ref-type="fig"}), suggesting that these cells were not Th2 or Treg cells. DP cells upregulated the expression of *TBX21,* which encodes T-bet that directs the differentiation of Th1 cells. Thus, these results indicate that DENV-specific DP cells may at least partially resemble Th1 cells.

The Frequency but Not the Gene Expression Profile of DP Cells Differs between DHF and DF {#S8}
----------------------------------------------------------------------------------------

We next investigated whether DP cells were associated with the DHF. The frequencies of IL-10 SP, IFN-γ SP, and total DENV-specific CD4 T cells were similar between DF and DHF during acute DENV infection, whereas the frequency of DP cells was significantly higher in acute DHF patients than in acute DF patients ([Figure 5A](#F5){ref-type="fig"}). Nevertheless, similar to DN cells, DENV-specific DP CD4 T cells isolated from acute DF and DHF patients displayed very similar gene expression profiles and clustered closely to one another based on PCA ([Figure 5B](#F5){ref-type="fig"}). Only 38 DE genes were identified when DP cells isolated from acute DF and DHF patients were directly compared ([Figure 5C](#F5){ref-type="fig"}). We also compared IL-10 SP and IFN-γ SP cells between DF and DHF. Consistently, only 7 and 46 DE genes were detected between DF and DHF when IL-10 SP and IFN-γ SP cells were compared, respectively ([Figure 5C](#F5){ref-type="fig"}). In addition, no significant difference was observed between DF and DHF in terms of the T cell receptor (TCR) repertoire diversity of DP cells ([Figure 5D](#F5){ref-type="fig"}). We next examined the abundances of the top five productive TCR β chain (TRB, which accounts for most of the TCR repertoire variation; [@R22]) clonotypes in each individual donor to investigate whether there were predominant TRB clonotypes. As shown in [Figure 5E](#F5){ref-type="fig"}, the abundances of the top five productive clonotypes varied between donors. We further identified a few predominant TRB clonotypes such as CASSRGAGEVQETQYF, CASSRPSGGELFF, CAISEPLKGYEQYF, and CASSLGQGARVDGYTF, which constituted 39.6%, 45.5%, 33.8%, and 42.5% of the antigen-specific TRB repertoires in GS1430, GS1431, GS1458, and GS1470, respectively ([Figure 5E](#F5){ref-type="fig"}; [Table S2](#SD1){ref-type="supplementary-material"}). Notably, none of these clonotypes were observed in two or more donors ([Table S2](#SD1){ref-type="supplementary-material"}). Future experiments are needed to investigate the antigen specificities of these predominant clonotypes. Although the magnitude of DENV-specific DP cell response may be higher in acute DHF samples, no major difference was observed in terms of the transcriptomic profile of DP cells, suggesting that severe dengue disease is not associated with the altered phenotype or function of DP cells.

Validation of DE Genes in DP Cells and High-Dimensional Single-Cell Analysis by CyTOF {#S9}
-------------------------------------------------------------------------------------

To validate the expression of DE genes in DENV-specific DP cells at the protein level, we performed cytometry by time-of-flight (CyTOF) analysis based upon selected DE genes for which antibodies were commercially available. We analyzed two independent sets of samples from two distinct geographical locations, namely Sri Lanka and Nicaragua. We focused our analysis on acute DHF samples, as DENV-specific DP cells were most abundant in these samples ([Figures 1C](#F1){ref-type="fig"} and [5A](#F5){ref-type="fig"}). We detected the production of IFN-γ and IL-10 using intracellular staining (ICS) after *ex vivo* stimulation with the DENV MP and identified DENV-specific IL-10^+^IFN-γ^+^ DP cells in both Sri Lankan and Nicaraguan cohorts ([Figure 6A](#F6){ref-type="fig"}), demonstrating that these cells may be a prominent antigen-specific CD4 T cell population that is commonly found in DHF patients at the acute stage, irrespective of geographic location. Furthermore, the CyTOF data validated the increased expression of several cytotoxic molecules, including granzyme B, perforin, and CCL3/CCL4 (the anti-CCL3 antibody used cross-reacts with CCL4) ([Figure 6B](#F6){ref-type="fig"}), Tr1-like cell-related molecules, including LAG-3, TIM-3, TIGIT, PD-1, ICOS, and CTLA-4 ([Figure 6C](#F6){ref-type="fig"}), as well as non-cytotoxic/Tr1 DE molecules, including IL-22, IL-22, CD86, CD70, IRF4, IRF8, CD109, and CCR1 ([Figures 6D](#F6){ref-type="fig"}--[6F](#F6){ref-type="fig"}) by DENV-specific DP cells at the protein level in the two cohorts from two different continents. As shown in [Figure 6G](#F6){ref-type="fig"}, DENV-specific DP cells also had increased protein expression of the transcription factors T-bet and Blimp-1, which promote the production of IFN-γ and IL-10, respectively ([@R40]; [@R60]).

Next, we investigated potential heterogeneity within the DENV-specific DP cell population at a single-cell level. To this end, we measured the expression of a total of 31 proteins for each individual cell, and the resulting high-dimensional data were visualized in 2-dimensional maps generated by the visualization of stochastic neighbor embedding (viSNE) ([@R2]). To obtain a sufficient number of cells for the viSNE analysis, we combined the data from both the Sri Lankan and Nicaraguan cohorts before running the viSNE analysis. As shown in [Figure 7A](#F7){ref-type="fig"}, DENV-specific DP cells were arranged largely as one "island" in the viSNE maps. In addition, we did not observe distinctive expression patterns for the majority of the protein markers, except for TIGIT and granzyme B, which exhibited gradient expression among DENV-specific DP cells ([Figure 7A](#F7){ref-type="fig"}). The cells with higher granzyme B expression also showed higher levels of perforin expression ([Figure 7A](#F7){ref-type="fig"}). The gradients of TIGIT and granzyme B appeared to be orthogonal, which prompted us to "gate" the DP cells according to the expression of TIGIT and granzyme B. As shown in [Figure 7B](#F7){ref-type="fig"}, \~50% of the DP cells co-express TIGIT and granzyme B. Furthermore, the majority of DENV-specific DP cells expressed low levels of CD45RA and CCR7, exhibiting a CD45RA^−^CCR7^−^ effector or effector memory T (Tem) phenotype ([Figures 7A](#F7){ref-type="fig"} and [7C](#F7){ref-type="fig"}), which was distinct from the Temra phenotype of cytotoxic CD4 T cells in DENV-exposed healthy individuals ([@R47]; [@R65]; [@R74]). These data show that DENV-specific DP cells are largely similar and homogeneous for the majority of the markers tested, despite the fact that these markers were selected to maximize the potential detection of different subsets. Nevertheless, varied expression patterns were observed for two of the markers analyzed, TIGIT and granzyme B.

DISCUSSION {#S10}
==========

This study reveals several important characteristics of virus-specific CD4 T cells during the acute phase of DENV infection. First, a prominent DENV-specific IL-10^+^IFN-γ^+^ DP CD4 T cell population is detected in patients with acute DENV infection, which becomes undetectable at the convalescent stage. Second, DENV-specific DP cells have a different gene expression profile by comparison with DN cells, whereas DENV-specific IFN-γ^+^ SP and IL-10^+^ SP cells display similar gene expression patterns to DP cells. Albeit at a much lower level, DENV-specific IFN-γ^+^ SP cells upregulate *IL10* gene expression. Conversely, DENV-specific IL-10^+^ SP cells upregulate *IFNG* gene expression, suggesting that these DENV-specific CD4 T cell populations may have a certain degree of plasticity and may be able to convert or transition into a different state. Third, although DENV-specific DP cells upregulate several cytotoxic CD4 T cell-associated and Tr1-like cell-associated molecules, the majority of DE genes such as *IL21, IL22, CD109,* and *CCR1* in DP cells were non-cytotoxic/Tr1. Fourth, although the frequency of DENV-specific DP cells is higher in DHF patients than in DF patients, the transcriptomic profile and TCR feature of DENV-specific DP cells are similar between DF and DHF, suggesting that severe dengue disease is not associated with altered phenotypic or functional attributes of DP cells. Nevertheless, we could not rule out the possibility that the increased frequency of DP cells by itself may increase disease severity. Finally, we validated the expression of several DE genes of DENV-specific DP cells at the protein level using CyTOF in two independent cohorts from two continents. These results further showed that DENV-specific DP cells appear to be a largely homogeneous population except for the expression of TIGIT and granzyme B, which showed gradient expression among DP cells. Collectively, we identified an intriguing DENV-specific IL-10^+^IFN-γ^+^ DP CD4 T cell population during acute DENV infection and characterized their transcriptomic and proteomic profiles as well as their association with severe DENV disease.

Previous studies have reported an increased frequency of Treg cells during acute DENV infection ([@R29]; [@R38]). Since DP cells lacked the expression of the master transcription factor gene of Treg cells *FOXP3* and *STAT5A* and *STAT5B,* our data indicate that they are distinct from Treg cells. We cannot rule out the possibility that the DP cell population may contain Tr1-like cells, as they share many molecular markers. It would be interesting to compare DP cells with Tr1-like cells from the same individuals. However, we were unable to distinguish them based on our CyTOF data at hand, supporting the notion that DP cells may contain Tr1-like cells.

IL-10^+^IFN-γ^+^ DP CD4 T cells have been previously reported in murine models of malaria, *Leishmania major, Toxoplasma gondii,* and chronic lymphocytic choriomeningitis virus (LCMV) infection ([@R4]; [@R17]; [@R28]; [@R46]), and in humans with malaria, tuberculosis, and *Borrelia burgdorferi* infection ([@R8]; [@R18]; [@R26], [@R27]; [@R49]; [@R71]). Malaria-specific DP cells are the most predominant in younger children who have a higher prior malaria incidence and have been recently exposed to malaria ([@R8]; [@R26]). In addition, children receiving antimalarial chemoprevention had reduced frequencies of DP cells ([@R27]), suggesting that DP cells are not associated with protection in the context of malaria. In the present study, we extend these findings and report antigen-specific DP CD4 T cells during an acute viral infection. We show that DENV-specific DP cells mainly exhibit a CD45RA^−^CCR7^−^ effector/Tem phenotype and upregulate both T-bet and Blimp-1 protein expression, which is consistent with previous findings on malaria-specific DP cells ([@R8]; [@R26]).

In addition to IL-10, DENV-specific DP cells showed an enhanced production of another member of the IL-10 family of cytokines---IL-22---which mainly acts on epithelial and stromal cells to mediate protection against various pathogens such as bacteria ([@R44]). IL-22 also has important functions in maintaining tissue homeostasis and facilitating tissue repair ([@R44]). Since severe dengue diseases are associated with tissue damage and plasma leakage ([@R58]), the IL-22 manufactured by DENV-specific DP cells may help to foster tissue regeneration. DENV-specific DP cells were also capable of producing IL-21, which exerts pleiotropic effects on the differentiation and function of both B and T cells ([@R57]; [@R62]; [@R61]). Notably, IL-21 plays important roles in promoting the generation of plasma cells and configuring germinal center (GC) and antibody responses by acting directly on GC B cells and indirectly on follicular CD4 T cell populations, including Tfh and follicular regulatory T (Tfr) cells ([@R57]; [@R61]). This is of interest in DENV infection because DENV-specific antibodies not only can neutralize the virus but also may exacerbate dengue pathogenesis via mechanisms that include antibody-dependent enhancement (ADE), depending upon their titer, affinity, and avidity ([@R58]). IL-21 also promotes the synthesis of IL-22 in CD4 T cells ([@R80]). Further studies will be necessary to define whether and how these cytokines secreted by DENV-specific DP cells modulate cellular and humoral immune responses against DENV and the development of dengue disease.

Previous studies have raised the concern that T cells may contribute to the pathogenesis of severe dengue disease, presumably via their production of proinflammatory cytokines, especially TNF ([@R53]). However, we did not detect upregulated *TNF* gene expression in DENV-specific DP cells in this study. Although the frequency of DENV-specific DP cells was higher in DHF patients than in DF patients, the gene expression profile of these cells remained largely unchanged, suggesting that DENV-specific DP cells may play a minimal role in the development of DHF. It should be noted that DSS cases were not analyzed in this study. Since we focused on DENV-specific CD4 T cells in this study, we cannot rule out the possibility that CD8 T cells may be associated with immunopathology. Moreover, although the functional significance of antigen-specific DP CD4 T cells and their role in protection and/or immunopathology after DENV infection warrants further investigation, one may speculate that DENV-specific CD4 T cells may upregulate IL-10 production as a compensatory mechanism to calm the excessive inflammation in DHF patients. It has been postulated that Th1 cells can upregulate the production of IL-10 to restrict inflammation at the expense of antigen persistence and that the relative production of IFN-γ and IL-10 regulates the balance between antigen clearance and immunopathology ([@R43]).

In summary, our results reveal an intriguing DENV-specific CD4 T cell subset that is capable of producing both the pro-inflammatory cytokine IFN-γ and the anti-inflammatory cytokine IL-10 during the acute phase of DENV infection. Our findings further demonstrate that the transcriptomic profile of these DP cells was similar in acute DF and DHF patients, arguing against the notion that altered CD4 T cell phenotype or function may be a determinant of DHF.

STAR★METHODS {#S11}
============

Detailed methods are provided in the online version of this paper and include the following:

LEAD CONTACT AND MATERIALS AVAILABILITY {#S12}
---------------------------------------

Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Yuan Tian (<ytian@lji.org>). This study did not generate new unique reagents.

EXPERIMENTAL MODEL AND SUBJECT DETAILS {#S13}
--------------------------------------

### Study approval {#S14}

Ethical approval to carry out this work is maintained through the La Jolla Institute for Immunology Institutional Review Board (protocols VD-085 and VD-101), the Medical Faculty of the University of Colombo (which served as a National Institutes of Health-approved institutional review board for Genetech and Kotelawala Defense University, protocols EC.15.002 and EC.15.095), the Nicaragua Ministry of Health (protocol CIRE-01/10/06--13.Ver14), and UC Berkeley Institutional Review Board (protocol 2010--06-1649). All clinical investigations have been conducted according to the principles expressed in the Declaration of Helsinki. All participants provided written informed consent prior to participation in the study.

### Human PBMC samples {#S15}

#### Sri Lanka acute donors {#S16}

All samples have been collected in the North Colombo Teaching Hospital, Ragama in Gampaha District, Sri Lanka and the National Institute of Infectious Diseases, Gothatuwa, Angoda, Sri Lanka. These donations are derived from small blood volumes (5--10 ml) from anonymous patients at the time of diagnosis/admission (median day 4 from fever onset; acute fever sample), at discharge from the hospital (median day 7 from fever onset), and after recovery from the disease (median day 31 from fever onset; convalescent sample) as outlined in [Table S3](#SD1){ref-type="supplementary-material"}. One group comprises patients that were diagnosed as uncomplicated dengue fever (DF) cases with no sign of bleeding or pleural effusion, while the other group was classified as dengue hemorrhagic fever (DHF).

#### Nicaragua acute donors {#S17}

Samples have been collected in The Hospital Infantil Manuel de Jesús Rivera (HIMJR) in the capital city of Managua. Acute fever samples have been collected on day 7 after fever onset. DHF was defined as fever with hemorrhagic manifestations, thrombocytopenia, and hemoconcentration or other signs of plasma leakage. The details of the donors used were listed in [Table S3](#SD1){ref-type="supplementary-material"}.

#### Sri Lanka healthy control donors {#S18}

Blood donations from five healthy adults from this dengue-endemic area were obtained from healthy adult blood donors from the National Blood Center, Ministry of Health, Colombo, Sri Lanka in an anonymous fashion as previously described ([@R73]). Donors were of both sexes and between 18 and 60 years of age. Seronegativity was confirmed by DENV specific IgG ELISAs and flow cytometry-based neutralization assays as previously described ([@R31]). The details of the donors used were listed in [Table S3](#SD1){ref-type="supplementary-material"}.

#### San Diego healthy control donors {#S19}

Blood donations from five healthy adults from this non-dengue-endemic area were obtained by the Clinical Studies Core at the La Jolla Institute for Immunology (LJI) in San Diego. The details of the donors used were listed in [Table S3](#SD1){ref-type="supplementary-material"}.

METHOD DETAILS {#S20}
--------------

### IFN-γ/IL-10 capture assay and cell sorting for RNA sequencing {#S21}

Human PBMCs were rested overnight at 37°C in RPMI 1640 medium (catalog\# RP-21, Omega Scientific, Inc.) supplemented with 5% human serum (catalog\# 100--512, Gemini Bio-Products), 2 mM L-alanyl-L-glutamine (GlutaMAX-I, catalog\# 35050061, Thermo Fisher Scientific), 100 U/ml penicillin, and 100 μg/ml streptomycin (catalog\# 400--109, Gemini Bio-Products) and subsequently stimulated with DENV MP (1 μg/ml for individual peptides) or Dynabeads Human T-Activator CD3/CD28 for T Cell Expansion and Activation (catalog\# 11132D, Thermo Fisher Scientific) for 3 h at 37°C. IFN-γ- and IL-10-producing cells were labeled using IFN-γ Secretion Assay - Detection Kit (PE), human (catalog\# 130--054-202, Miltenyi Biotech) and IL-10 Secretion Assay -- Detection Kit (APC), human (catalog\# 130--090-761, Miltenyi Biotech), respectively, according to the manufacturer's instructions. Subsequently, PBMCs were stained with anti-human CD3, CD4, CD8, CD14, CD19, CD45RA, and CCR7 (see [Table S4](#SD1){ref-type="supplementary-material"} for antibody details). CD4 IL-10^−^IFN-γ^−^ DN, IL-10^+^IFN-γ^−^ IL-10 SP and IL-10^−^IFN-γ^+^ IFN-γ SP, and IL-10^+^IFN-γ^+^ DP cells were sorted using a FACSAria II cell sorter. Data were analyzed using FlowJo.

### Microscaled RNA sequencing {#S22}

For each condition, 100 cells were directly collected at 4°C in 8 μL of lysis buffer composed by 0.2% Triton X-100, 2 U/μl of recombinant RNase inhibitor (Takara), 5 mM dNTP mix (Life Technologies) in 0.2 mL PCR tube (Maxymum recovery, Axygen). Right after sort, tubes were vortexed at medium speed, spun, and stored at −80°C until the completion of the whole set of samples. Microscaled RNA-Seq library preparation was performed in technical duplicates for each biological condition. Briefly, 4 μL of each sample was amplified following the Smart-seq2 protocol ([@R48]; [@R52]). mRNA was captured using poly-dT oligos and directly reverse-transcribed into full-length cDNA using the described template-switching oligo ([@R48]; [@R52]). cDNA was amplified by PCR for 19 cycles and purified using AMPure XP magnetic bead (0.9:1 (vol:vol) ratio, Beckman Coulter). From this step, for each sample, 1 ng of cDNA was used to prepare dual-index barcoded standard NextEra XT libraries (NextEra XT DNA library prep kit and index kits; Illumina). Both whole-transcriptome amplification and sequencing library preparations were performed in a 96-well format to reduce assay-to-assay variability. Quality control steps were included to determine the optimal number of PCR preamplification cycles, and library fragment size. Samples that failed quality controls were eliminated from downstream steps. Library that passed strict quality controls were pooled at equimolar concentration, loaded and sequenced on the Illumina Sequencing platform, HiSeq2500 (Illumina). Technical libraries were sequenced and technical duplicate datasets merged in order to obtain more than 15 million 50-bp single-end reads (HiSeq Rapid Run Cluster and SBS Kit V2; Illumina) mapping uniquely to human transcriptome reference (GRCh38.gencode.v27B), generating a total of about 1.2 billion mapped reads.

### RNA-sequencing analysis {#S23}

The single-end reads that passed Illumina filters were filtered for reads aligning to tRNA, rRNA, adaptor sequences, and spike-in controls. The reads were then aligned to GRCh38 reference genome and Gencode 27 annotations using TopHat v1.4.1 ([@R67]). DUST scores were calculated with PRINSEQ Lite v0.20.3 ([@R54]) and low-complexity reads (DUST \> 4) were removed from the BAM files. The alignment results were parsed via the SAMtools ([@R35]) to generate SAM files. Read counts to each genomic feature were obtained with the htseq-count program ([@R3]) using the "union" option. After removing absent features (zero counts in all samples), the raw counts were then imported to DESeq2 to identify differentially expressed genes between groups ([@R37]). The shrinkage estimator apeglm was used to generate the shrunken log2 fold changes and compute *s*-values ([@R86]). *s*-values provide the estimated rate of false sign among genes with equal or smaller *s*-value and are analogous to *q*-values ([@R59]). Genes with an *s*-value of \< 0.005 and a shrunken log2 fold change of \> 1 or \< −1 were considered significantly differentially expressed between groups. Enrichment analysis was performed using Metascape ([@R85]).

### CyTOF {#S24}

PBMCs were stimulated with DENV MP (1 μg/ml for individual peptides) in the presence of brefeldin A (GolgiPlug, BD Biosciences, catalog\# 51--2301KZ) for 6 h. Cells were then stained with the viability marker Cisplatin (194Pt, Fluidigm, catalog\# 201194) followed by a surface antibody cocktail. Subsequently, cells were fixed in PBS with 2% paraformaldehyde overnight at 4°C. The following day, cells were stained with an intracellular/intranuclear antibody cocktail after fixation and permeabilization using the Foxp3/Transcription Factor Staining Buffer Set (eBioscience, catalog\# 00--5523-00). Before sample acquisition, cellular DNA was labeled with Cell-ID Intercalator-Ir (Fluidigm, catalog\# 201192B). Samples were then acquired using a Helios mass cytometer (Fluidigm) with the wide-bore injector ([@R34]). Antibodies used in CyTOF were listed in [Table S5](#SD1){ref-type="supplementary-material"}. Data were analyzed using FlowJo and viSNE analysis of CyTOF data was conducted using Cytobank ([@R30]).

### TCR analysis {#S25}

MiXCR ([@R6], [@R7]) was used to extract TCR beta-chain CDR3 repertoires from RNA-seq data of sorted CD4 T cell subsets. Subsequent TCR beta-chain diversity analysis was performed using VDJtools ([@R56]).

QUANTIFICATION AND STATISTICAL ANALYSIS {#S26}
---------------------------------------

Two-tailed Mann-Whitney (unpaired) or Wilcoxon (paired) test was used to determine statistical significance between groups using the Prism software (GraphPad, La Jolla, CA). Statistical details of experiments can be found in the figure legends. Statistical details of differential gene expression analysis can be found in the [Method Details](#S20){ref-type="sec"}.

DATA AND CODE AVAILABILITY {#S27}
--------------------------

The accession number for the RNA-sequencing data reported in this paper is Gene Expression Omnibus (GEO): GSE132367 and ImmPort: SDY 888. The accession number for the CyTOF data reported in this paper is ImmPort: SDY 888.
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![Identification of Human DENV-Specific IL-10^+^IFN-γ^+^ Double-Positive (DP) CD4 T Cells during the Acute Phase of Infection\
Human PBMCs isolated from DENV-infected patients at acute, discharge, and convalescent stages were stimulated with DENV MP, and DENV-specific CD4 T cells were identified by the production of IFN-γ and/or IL-10 using flow cytometry.\
(A) Flow cytometry plot shows the production of IFN-γ and IL-10 by CD4 T cells during the acute phase.\
(B) Bar graph shows the frequencies of DENV-specific IL-10 SP, IFN-γ SP, and DP cells among acute samples (n = 17).\
(C) Bar graphs show the frequencies of IL-10 SP, IFN-γ SP, DP, and total cytokine-positive cells at acute, discharge (dis), and convalescent (conv) stages (n = 17).\
Error bars show medians with interquartile ranges. Statistical significance was determined by two-tailed Wilcoxon test. ns, not significant, \*p \< 0.05, \*\*p \< 0.01, \*\*\*p\<0.001,\*\*\*\*p\<0.0001.](nihms-1547521-f0002){#F1}

![Gene Expression Profiles of DENV-Specific CD4 T Cell Subsets\
(A) PCA analysis of gene expression data of DN (n = 20), IL-10 SP (n = 12), IFN-γ SP (n = 15), and DP cells (n = 10). N indicates the number of samples.\
(B) Volcano plots show log2 fold changes versus −log10 s values for the comparisons between DP and DN, IL-10 SP and DP, IFN-γ SP and DP, IFN-γ SP and IL-10 SP, IFN-γ SP and DN, and IL-10 SP and DN. Genes with a log2 fold change of \>3.3 or \<−3.3 and an s value of \<0.005 were considered significant and are shown in red. Numbers indicate the number of significant DE genes, and the numbers in parentheses indicate the percentages of significant DE genes (a total of 7,755 genes were analyzed).\
(C) Heatmap shows the expression values after variance stabilizing transformation of the top 250 DE genes between DP and DN cells. Colored genes were associated with naive/memory T cells (blue), activation (black), cytokines and chemokines (green), co-stimulation/inhibition (purple), cytotoxicity (red).](nihms-1547521-f0003){#F2}

![Non-cytotoxic/Tr1 DE Genes in DP Cells Are Associated with Cytokine Production, Activation, Function, and Migration\
(A) Volcano plot shows log2 fold changes versus −log10 s values for the comparisons between DP and DN with selected non-cytotoxic/Tr1 DE genes labeled. Significant DE genes are shown in red.\
(B) Enrichment analysis results of the 224 non-cytotoxic/Tr1 DE genes.\
(C--E) Bar graphs show the gene expression values in counts normalized by sequencing depth that is calculated by DESeq2 for (C) cytotoxicity-related,\
(D) activation/function-related, and (E) migration-related genes in DN and DP cells. Error bars show medians with interquartile ranges. A pseudocount of 0.5 was added to allow for plotting in log scale. Statistical significance was determined by DESeq2 using the shrinkage estimator apeglm, and the computed s values were indicated in the graphs.](nihms-1547521-f0004){#F3}

![Expression Levels of Transcription Regulators of Various CD4 T Cell Lineages by DENV-Specific DP Cells\
Bar graphs show gene expression values in transcripts per million (TPM) for various transcription factors in DN cells (n = 20) and DP cells (n = 10). Error bars show medians with interquartile ranges. Statistical significance was determined by two-tailed Mann-Whitney test. ns, not significant, \*\*p \< 0.01, \*\*\*p \< 0.001, \*\*\*\*p \< 0.0001.](nihms-1547521-f0005){#F4}

![The Frequency of DENV-Specific DP Cells Is Higher in Acute DHF Patients Than in DF Patients\
(A) Bar graphs show the percentages of IL-10 SP, IFN-γ SP, DP, and total cytokine-positive cells among acute DF (n = 13) and DHF (n = 13) samples.\
(B) PCA of the gene expression data of DN cells (left panel) and DP cells (right panel) colored by DF and DHF (n = 10, 10, 3, and 7 for DN-DF, DN-DHF, DP-DF, and DP-DHF, respectively).\
(C) Volcano plot shows log2 fold changes versus −log10 s values for the comparisons between DP-DHF and DP-DF (left panel), IL-10 SP-DHF (n = 7) and IL-10 SP-DF (n = 5) (center panel), and IFN-γ SP-DHF (n = 8) and IFN-γ SP-DF (n = 7) (right panel). Significant DE genes were shown in red.\
(D) Dot plots show the observed diversity of the TCR *α* chain (TRA, left panel) and β chain (TRB, right panel) repertoires of DP cells in DF and DHF samples (n = 3 and 7 for DP-DF and DP-DHF, respectively).\
(E) Bar graph shows the abundances of the top five TRB clonotypes in each donor.\
Error bars show medians with interquartile ranges. Statistical significance was determined by two-tailed Mann-Whitney test. ns, not significant, \*p \< 0.05.](nihms-1547521-f0006){#F5}

![Validation of DE Genes in DENV-Specific DP Cells at the Protein Level\
Human PBMCs isolated from Sri Lankan (SL, n = 5) and Nicaraguan (NI, n = 5) patients with acute DENV infection were stimulated with DENV MP, and the expression of various molecules was measured by CyTOF.\
(A) Dot plots show the production of IFN-γ and IL-10 by CD4 T cells.\
(B--G) Bar graphs show the protein expression in geometric mean values for molecules related to (B) cytotoxicity, (C) Tr1-like cells, (D) cytokines, (E) T cell activation/function, (F) migration, and (G) transcription factors in DN and DP cells.\
Error bars show medians with interquartile ranges. Statistical significance was determined by two-tailed Mann-Whitney test. \*\*p \< 0.01.](nihms-1547521-f0007){#F6}

![DENV-Specific DP Cells Are Largely Homogeneous, Except for the Expression of TIGIT and Granzyme B\
DP cells were merged from five Sri Lankan and five Nicaraguan donors.\
(A) viSNE analysis was performed on DP cells based on the expression of 31 proteins. Plots show the expression of these 31 proteins in each individual cell.\
(B) Contour plot shows the expression of TIGIT and granzyme B by DP cells. Numbers indicate the percentages of cells in each quadrant.\
(C) Dot plots show the expression of CD45RA and CCR7 on total CD4 T cells (left panel) and DP cells (right panel). Numbers indicate the percentages of cells in each quadrant.](nihms-1547521-f0008){#F7}

  REAGENT or RESOURCE                                                        SOURCE                     IDENTIFIER
  -------------------------------------------------------------------------- -------------------------- -------------------------------------------------------------------
  Antibodies                                                                                            
  CD3, Alexa Fluor 700                                                       BioLegend                  Cat\#317340; Clone OKT3; RRID: AB_2563408
  CD4, APC eFluor 780                                                        eBioscience                Cat\#47--0049--42; Clone RPA-T4; RRID: AB_1272044
  CD8, Brilliant Violet 650                                                  BioLegend                  Cat\#301042; Clone RPA-T8; RRID: AB_2563505
  CD14, V500                                                                 BD Biosciences             Cat\#561391; Clone M5E2; RRID: AB_10611856
  CD19, V500                                                                 BD Biosciences             Cat\#561121; Clone HIB19; RRID: AB_10562391
  CD45RA, eFluor 450                                                         eBioscience                Cat\#48--0458--42; Clone HI100; RRID: AB_1272059
  CCR7, PerCP Cy5.5                                                          BioLegend                  Cat\#353220; Clone G043H7; RRID: AB_10916121
  CD14, 89Y                                                                  Biolegend                  Cat\#301802; Clone M5E2; RRID: AB_314184
  CD19, 89Y                                                                  Biolegend                  Cat\#302247; Clone HIB19; RRID: AB_2562815
  CD3, 115In                                                                 Biolegend                  Cat\#300402; Clone UCHT1; RRID: AB_314056
  CD223/LAG3, 141Pr                                                          Biolegend                  Cat\#369302; Clone 11C3C65; RRID: AB_2616876
  TCF7, 142Nd                                                                Biolegend                  Cat\#655202; Clone 7F11A10; RRID: AB_2562103
  IL-7R (CD127), 143Nd                                                       Fluidigm                   Cat\#3143012B; Clone A019D5; RRID: AB_2810240
  CD70, 144Nd                                                                Biolegend                  Cat\#355102; Clone 113--16; RRID: AB_2561429
  CD4, 145Nd                                                                 Fluidigm                   Cat\#3145001B; Clone RPA-T4; RRID: AB_2661789
  CD8a, 146Nd                                                                Fluidigm                   Cat\#3146001B; Clone RPA-T8; RRID: AB_2687641
  IRF4, 147Sm                                                                Biolegend                  Cat\#646402; Clone IRF4.3E4; RRID: AB_2280462
  CD278/ICOS, 148Nd                                                          Fluidigm                   Cat\#3148019B; Clone C398.4A; RRID: AB_2756435
  CD30/TNFRSF8, 149Sm                                                        R&D Systems                Cat\#MAB229; Clone 81337; RRID: AB_2207591
  IL-22, 150Nd                                                               Fluidigm                   Cat\#3150007B; Clone 22URTI; RRID: AB_2810972
  CCR1, 151Eu                                                                R&D Systems                Cat\#MAB145--100; Clone 53504; RRID: AB_2074021
  CX3CR1, 152Sm                                                              Biolegend                  Cat\#341602; Clone 2A9--1; RRID: AB_1595422
  TIGIT, 153Eu                                                               Fluidigm                   Cat\#3153019B; Clone MBSA43; RRID: AB_2756419
  HAVCR2 (TIM-3/CD366), 154Sm                                                Fluidigm                   Cat\#3154010B; Clone F38--2E2
  IRF8, 155Gd                                                                Biolegend                  Cat\#656502; Clone 7G11A45; RRID: AB_2562395
  CD86, 156Gd                                                                Fluidigm                   Cat\#3156008B; Clone IT2.2; RRID: AB_2661798
  CD137, 158Gd                                                               Fluidigm                   Cat\#3158013B; Clone 4B4--1
  CD357/GITR, 159Tb                                                          Fluidigm                   Cat\#3159020B; Clone 621
  T-bet, 160Gd                                                               Fluidigm                   Cat\#3160010B; Clone 4B10; RRID: AB_2810251
  CD109, 161Dy                                                               R&D Systems                Cat\#MAB4385; Clone 496920; RRID: AB_10645622
  Foxp3, 162Dy                                                               Fluidigm                   Cat\#3162024A; Clone 259D/C7
  TGFbeta, 163Dy                                                             Fluidigm                   Cat\#3163010B; Clone TW4--6H10
  CXCR5 (CD185), 164Dy                                                       Fluidigm                   Cat\#3164016B; Clone 51505; RRID: AB_2687858
  IFNg, 165Ho                                                                Fluidigm                   Cat\#3165002B; Clone B27
  IL-10, 166Er                                                               Fluidigm                   Cat\#3166008B; Clone JES3--9D7
  CCR7 (CD197), 167Er                                                        Fluidigm                   Cat\#3167009A; Clone G043H7
  Ki-67, 168Er                                                               Fluidigim                  Cat\#3168001B; Clone Ki-67; RRID: AB_2810856
  CD45RA, 169Tm                                                              Fluidigim                  Cat\#3169008B; Clone HI100
  CD152 (CTLA-4), 170Er                                                      Fluidigm                   Cat\#3170005B; Clone 14D3
  BLIMP1, 171Yb                                                              Novus                      Cat\#NB600--235; Clone 3H2-E8; RRID: AB_10595225
  IL-21, 172Yb                                                               Fluidigm                   Cat\#3172011B; Clone 3A3-N2; RRID: AB_2810975
  Granzyme B, 173Yb                                                          Fluidigm                   Cat\#3173006B; Clone GB11; RRID: AB_2811095
  CD279 (PD-1), 174Yb                                                        Fluidigm                   Cat\#3174020B; Clone EH12.2H7
  Perforin, 175Lu                                                            Fluidigm                   Cat\#3175004B; Clone B-D48
  CCL3/CCL4, 176Yb                                                           R&D Systems                Cat\#MAB2701--100; Clone 93342; RRID: AB_2259652
  Chemicals, Peptides, and Recombinant Proteins                                                         
  RPMI 1640 medium                                                           Omega Scientific, Inc.     Cat\#RP-21
  Human serum                                                                Gemini Bio-Products        Cat\#100--512
  GlutaMAX-I                                                                 Thermo Fisher Scientific   Cat\#35050061
  Penicillin and streptomycin                                                Gemini Bio-Products        Cat\#400--109
  DENV MP                                                                    [@R20]; [@R75]             N/A
  Brefeldin A (GolgiPlug)                                                    BD Biosciences             Cat\#51--2301KZ
  Cisplatin-194Pt                                                            Fluidigm                   Cat\#201194
  Intercalator-Ir                                                            Fluidigm                   Cat\#201192B
  Foxp3/Transcription Factor Staining Buffer Set                             eBioscience                Cat\#00--5523--00
  Critical Commercial Assays                                                                            
  Dynabeads Human T-Activator CD3/CD28 for T Cell Expansion and Activation   Thermo Fisher Scientific   Cat\#11132D
  IFN-γ Secretion Assay -- Detection Kit (PE), human                         Miltenyi Biotech           Cat\# 130--054--202
  IL-10 Secretion Assay -- Detection Kit (APC), human                        Miltenyi Biotech           Cat\# 130--090--761
  Deposited Data                                                                                        
  RNA-seq data                                                               This paper                 GEO: GSE132367; ImmPort: SDY 888
  CyTOF data                                                                 This paper                 ImmPort: SDY 888
  Software and Algorithms                                                                               
  FlowJo v10                                                                 FlowJo, LLC                <https://www.flowjo.com/>
  GraphPad Prism 8                                                           GraphPad software          <https://www.graphpad.com/>
  DESeq2                                                                     [@R37]                     <https://bioconductor.org/packages/release/bioc/html/DESeq2.html>
  Metascape                                                                  [@R85]                     <http://metascape.org/gp/index.html#/main/step1>
  Cytobank                                                                   [@R30]                     <https://www.cytobank.org/>
  MiXCR                                                                      [@R6], [@R7]               <https://mixcr.readthedocs.io/en/master/>
  VDJtools                                                                   [@R56]                     <https://vdjtools-doc.readthedocs.io/en/master/>

###### Highlights

-   DENV-specific IL-10^+^IFN-γ^+^ DP CD4 T cells are prominent during acute disease

-   Most DP cell DE genes are non-cytotoxic/Tr1 and include *IL21, IL22, CD109,* and CCR1

-   DP cells have similar gene expression in DF and DHF, despite higher frequency in DHF

-   Disease severity is not associated with altered DP cell phenotype or functionality
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